Effects of empagliflozin on overall heart failure burden in EMPA-REG OUTCOME

Back

ESC Premium Access

Effects of empagliflozin on overall heart failure burden in EMPA-REG OUTCOME

Session: Clinical Trial Update Heart failure and Pacing

Topic: Pharmacologic therapy

Speaker: Doctor D. Fitchett (Toronto, CA)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

6 more presentations in this session

Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS treated with cardiac resynchronization therapy: analysis of the EchoCRT trial

Speaker: Professor J. Bax (Leiden, NL)

Access

Slides

Video

Long-term Performance of a Transcatheter Pacing System: 12 Month Results From the Micra Global Clinical Trial

Speaker: Doctor P. Ritter (Bordeaux, FR)

Access

Slides

Video

Association between risk reduction in cardiovascular deaths or hospitalizations and CRT optimization using the SonR contractility sensor in subgroups of patients: RESPOND-CRT Trial update

Speaker: Professor J. Brugada Terradellas (Barcelona, ES)

Access

Slides

Video

Effects of Empagliflozin on Cardiovascular Mortality by Prevalent or Incident Heart Failure in EMPA-REG OUTCOME

Speaker: Doctor D. Fitchett (Toronto, CA)

Access

Slides

Echocardiographic Progression and Effects of Etiologic Treatment in Chagas Cardiomyopathy: A BENEFIT Trial Echocardiographic Sub-Study

Speaker: Associate Professor A. Schmidt (Ribeirao Preto, BR)

Access

Slides

Video

Access the full session

Clinical Trial Update Heart failure and Pacing

Speakers: Doctor D. Fitchett, Professor J. Bax, Doctor P. Ritter, Professor J. Brugada Terradellas, Doctor D. Fitchett...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources